A case report of telitacicept in the treatment of immunocompromised and refractory lupus nephritis
Lupus nephritis (LN) is a manifestation of kidney damage in systemic lupus erythematosus and is more common in Asian populations. The standard-of-care (SOC) for LN includes antimalarials, glucocorticoids, and immunosuppressants. The efficacy and safety of biologics have been validated, and they play...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2025-11-01
|
| シリーズ: | Frontiers in Immunology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1676486/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|